Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 1/20 | 0.50 |
| ▸ | SSTR4 | P31391 | 13/20 | 0.48 |
| ▸ | SSTR2 | P30874 | 12/20 | 0.48 |
| ▸ | SSTR5 | P35346 | 11/20 | 0.48 |
| ▸ | SSTR3 | P32745 | 11/20 | 0.48 |
| ▸ | SSTR1 | P30872 | 5/20 | 0.48 |
| ▸ | OXTR | P30559 | 1/20 | 0.46 |
| ▸ | LDLR | P01130 | 4/20 | 0.46 |
| ▸ | PCSK9 | Q8NBP7 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26814255 | 0.83 | SSTR2 (0.54) | SSTR4SSTR2SSTR5SSTR3SSTR1 | |
| SCHEMBL20963290 | 0.83 | SSTR2 (0.48) | CACNA1BSSTR4SSTR2SSTR5SSTR3 | |
| SCHEMBL21312758 | 0.82 | OXTR (0.58) | CACNA1BSSTR4SSTR2SSTR5SSTR3 | |
| SCHEMBL22844368 | 0.82 | OXTR (0.58) | CACNA1BSSTR4SSTR2SSTR5SSTR3 | |
| SCHEMBL20465794 | 0.81 | SSTR2 (0.70) | SSTR4SSTR2SSTR5SSTR3SSTR1 | |
| SCHEMBL21892055 | 0.81 | SSTR2 (0.70) | SSTR4SSTR2SSTR5SSTR3SSTR1 | |
| SCHEMBL22183489 | 0.80 | SSTR2 (0.69) | SSTR4SSTR2SSTR5SSTR3SSTR1 | |
| SCHEMBL19543950 | 0.78 | SSTR2 (0.61) | SSTR4SSTR2SSTR5SSTR3SSTR1 | |
| SCHEMBL18712623 | 0.78 | SSTR5 (0.50) | CACNA1BSSTR2SSTR5SSTR3SSTR1 | |
| SCHEMBL23968131 | 0.77 | OXTR (0.59) | SSTR2SSTR5OXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11160871-B2 | SSTR-targeted conjugates and particles and formulations thereof | TARVEDA THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20180221499-A1 | SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221499-A1 | SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | SSTR1, SSTR4, SSTR3 | CACNA1B 4481/4885SSTR4 2/4885SSTR2 5/4885 |
| US-11160871-B2 | SSTR-targeted conjugates and particles and formulations thereof | SSTR1, SSTR4, SSTR3 | CACNA1B 4481/4885SSTR4 2/4885SSTR2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.